In a major enforcement action, the U.S. Attorney for the Southern District of New York, Damian Williams, announced a $202 million civil settlement with Gilead Sciences, Inc. over allegations that the company used speaker programs to funnel improper payments and benefits to healthcare providers in order to boost prescriptions of its HIV medications.
The settlement resolves alleged violations of the Anti-Kickback Statute (AKS) and the False Claims Act (FCA). The government claimed these practices resulted in millions of dollars in false claims billed to federal healthcare programs.
(Note: The DOJ emphasizes these were allegations; the settlement is not an admission of liability.)
The Allegations Against Gilead Sciences
According to the DOJ, Gilead operated HIV Speaker Programs and HIV Dinner Programs that were purported to be educational but were instead used to provide:
- Paid speaking engagements
- Meals, alcohol, and travel benefits
- Events at luxury restaurants (e.g., James Beard House, Del Posto)
- Trips to desirable destinations such as Hawaii, Miami, and New Orleans
The DOJ found that these programs often delivered minimal educational content and were structured in ways that created improper financial incentives for physicians to prescribe Gilead’s HIV medications, including Stribild®, Genvoya®, Complera®, Odefsey®, Descovy®, and Biktarvy®.
Gilead also allegedly failed to enforce its own compliance controls, allowing improper conduct to persist between 2011 and 2017.
Under the terms of the settlement, Gilead will pay:
-
$176,927,889.28 to the United States
-
The remainder to participating states that suffered Medicaid-related losses
What the DOJ Investigation Revealed
The government’s investigation found several patterns:
-
Repeat attendance: More than 250 healthcare providers attended Gilead dinner programs multiple times, often on the exact same topic within six months.
-
Lavish perks: Some events featured expensive meals, alcohol, and paid travel, even at locations selected by the speaker.
-
High-volume prescribers: One HIV speaker received over $300,000 in honoraria, while their prescriptions resulted in more than $6 million in payments from Medicare, Medicaid, and TRICARE.
The DOJ did not state that all or many attendees received honoraria—only that speakers received these payments. Many attendees instead received meals and hospitality benefits.
The government alleged these benefits were intended to induce physicians to prescribe Gilead’s drugs, causing federally funded programs to pay millions in tainted claims.
The Critical Role of Whistleblowers
This settlement arose from a whistleblower lawsuit filed under the False Claims Act. The DOJ intervened after reviewing evidence presented by the whistleblower.
Whistleblowers are often the first line of defense in exposing:
-
Kickback schemes
-
Unlawful marketing practices
-
Billing fraud
-
Misuse of taxpayer funds
Under the False Claims Act, individuals who provide original information leading to government recovery may be eligible to receive a portion of the settlement.
This case underscores how essential whistleblowers are in uncovering fraud that would otherwise remain hidden.
Reporting Healthcare Fraud
Fraudulent schemes—such as illegal kickbacks, false billing, or sham “speaker programs”—drive up healthcare costs and undermine patient trust.
If you have information about potential violations involving the False Claims Act or Anti-Kickback Statute, you may have the right to file a confidential whistleblower claim.
The Whistleblower Advocates represents individuals who want to report fraud while protecting their anonymity and legal rights. Our team offers free and confidential consultations to help you evaluate your case.
Contact The Whistleblower Advocates today to learn more about your options and how whistleblowers can help safeguard federal healthcare programs.
Source: https://www.justice.gov/usao-sdny/pr/us-attorney-announces-202-million-settlement-gilead-sciences-using-speaker-programs?link_id=10&can_id=f87aac00a044a0da0c451889dc4f075a&source=email-walgreens-to-pay-up-to-350-million-to-settle-fca-opioid-allegations&email_referrer=email_2720173___from_3222588&email_subject=fraud-in-america-whistleblower-teresa-ross&&
This article is a news article for informational purposes only. The Whistleblower Advocates did not represent the parties identified in the story above.
